Clinical Trials Logo

Lymphoma clinical trials

View clinical trials related to Lymphoma.

Filter by:

NCT ID: NCT03381768 Completed - Follicular Lymphoma Clinical Trials

Peptide Vaccination Against PD-L1 and PD-L2 in Relapsed Follicular Lymphoma

Start date: December 12, 2017
Phase: Phase 1
Study type: Interventional

An open phase-1, first-in-human, clinical trial investigating the safety and immunological effects of peptide vaccination with Programmed Death Ligand 1 and 2 (PD-L1 and PD-L2) peptides in patients with relapsed follicular lymphoma.

NCT ID: NCT03380026 Completed - Mycosis Fungoides Clinical Trials

Mechlorethamine Induced Contact Dermatitis Avoidance Study

MIDAS
Start date: December 13, 2017
Phase: Phase 2
Study type: Interventional

This is a two-arm, open-label study that aims to compare the incidence and severity of the most common adverse reactions, particularly contact dermatitis, when Valchlor is used alone or in conjunction with triamcinolone ointment 0.1% in early stage MF subjects (Stage IA and IB) for a period of 4 months.

NCT ID: NCT03376958 Completed - Clinical trials for Diffuse Large B Cell Lymphoma

Apatinib for Relapsed and Refractory Diffuse Large B Cell Lymphoma

Start date: January 1, 2017
Phase: Phase 4
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of Apatinib for patients with Relapsed Refractory Diffuse Large B Cell Lymphoma.

NCT ID: NCT03374137 Completed - Clinical trials for Chronic Lymphocytic Leukemia

Observational Study to Monitor Safety and Effectiveness of Obinutuzumab in Follicular Lymphoma or Previously Untreated Chronic Lymphocytic Leukemia

Start date: March 9, 2018
Phase:
Study type: Observational

This study aims to collect clinical data, mainly focused on safety, in the local target population as per the requirement of Korea Ministry of Food and Drug Safety for market authorization. The study population comprises patients with approved local indications chronic lymphocytic leukemia (CLL) and/or follicular lymphoma (FL) in routine clinical practice after launch.

NCT ID: NCT03372837 Completed - Clinical trials for Assess the Efficacy and Safety of SyB L-0501 in Combination With Rituximab in Patients With Recurrent or Relapsed DLBCL

Phase III Study of SyB L-0501 in Combination With Rituximab to Treat Recurrent/Relapsed Diffuse Large B-Cell Lymphoma

Start date: January 15, 2018
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine the efficacy of SyB L-0501 in combination with rituximab in patients with recurrent/relapsed diffuse large B-cell lymphoma.

NCT ID: NCT03372057 Completed - Clinical trials for Peripheral T-cell Lymphoma

A Study of Duvelisib in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)

PRIMO
Start date: February 22, 2018
Phase: Phase 2
Study type: Interventional

This is a multi-center, parallel cohort, open-label, Phase 2 study of duvelisib, an oral dual inhibitor of PI3K-δ,γ, in patients with relapsed/refractory Peripheral T-cell Lymphoma (PTCL).

NCT ID: NCT03365791 Completed - Clinical trials for Small Cell Lung Cancer

PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies

Start date: January 24, 2018
Phase: Phase 2
Study type: Interventional

The purpose of this signal seeking study is to determine whether treatment with PDR001 and LAG525 demonstrates sufficient efficacy in advanced malignancies to warrant further study.

NCT ID: NCT03364439 Completed - Clinical trials for Diffuse Large B Cell Lymphoma

R-CHOP14 or R-CHOP21 &Consolidation PET-Oriented Radiotherapy (RT) in DLBCL Patients

FIL_DLCL10
Start date: January 2012
Phase: Phase 2
Study type: Interventional

Prospective, multicentre phase II study with R-CHOP- 14 or R-CHOP-21 & consolidation PET-oriented radiotherapy (RT) in diffuse large B cell lymphoma (DLBCL) patients

NCT ID: NCT03364231 Completed - Clinical trials for Marginal Zone Lymphoma

Study to Assess the Efficacy and Safety of Umbralisib in Participants With Non-Follicular Indolent Non-Hodgkin's Lymphoma

Start date: November 30, 2017
Phase: Phase 2
Study type: Interventional

This research study will evaluate the safety and efficacy of a study drug called Umbralisib (also known as TGR-1202) alone as a possible treatment for Waldenstrom's Macroglobulinemia that has come back or that has not responded to standard treatment.

NCT ID: NCT03361358 Completed - Lymphoma Clinical Trials

Pre-Screening Study to Identify MTAP Loss in Advanced Solid Tumors or Lymphoma

Start date: March 1, 2018
Phase:
Study type: Observational

The purpose of this study is to identify subjects with advanced solid tumors or lymphoma in which the methylthioadenosine phosphorylase (MTAP) protein has been lost.